Navigation Links
Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth
Date:2/23/2011

OAKLAND, Tenn., Feb. 23, 2011 /PRNewswire/ -- Plexus Biomedical Inc. has been granted a new classification and approval from the Food and Drug Administration to market the first device clinically shown to help prevent external hemorrhoids during vaginal childbirth. Hemorrhoids associated with vaginal delivery are a frequent complication of childbirth and affect between 750,000 and 1,000,000 pregnant women in the U.S. every year.

The patented Hem-Avert® Perianal Stabilizer supports the perianal region of the patient during labor and delivery.  The unique device is easily applied, completely external and will soon be available to physicians and hospitals nationwide.

CEO David Blurton stated, "Since there were not any competitive products or predicate devices that addressed delivery-induced hemorrhoids, the company conducted a prospective, randomized, multicenter clinical study to provide the clinical data necessary for the FDA to create a new classification for the device through its de novo 510(k) process."

Findings from the clinical study showed that none of the women randomly chosen to use the Hem-Avert® device during labor and delivery developed hemorrhoids.  By contrast, 25% of the women in the control group who delivered without the Hem-Avert® device developed hemorrhoids as a direct result of vaginal delivery, a finding consistent with the reported incidence of hemorrhoids documented in medical literature.

The high incidence of delivery-induced hemorrhoids among all vaginal births yields a potential U.S. market in excess of $650M.  When combined with vaginal births from Canada and Europe, the potential market for the Hem-Avert® device doubles to $1.3B. The company believes better patient outcomes, cost savings, and patient demand will all contribute to the product's success.

Plexus Biomedical is dedicated to revolutionizing obstetrics by eliminating or reducing common problems and morbidities associated with childbirth.  The company already has two issued United States Patents covering the Hem-Avert® Perianal Stabilizer with additional patent applications pending in the United States and internationally.

For additional information visit www.hem-avert.com or contact Plexus Biomedical, Inc.

David Blurton

(901) 763-2900 or (877) 844-4767

info@plexusbiomedical.com



Indication for Use: The Hem-Avert® Perianal Stabilizer is designed to provide counter-pressure to the anus during vaginal childbirth.  This counter-pressure force helps prevent the occurrence of external hemorrhoids during vaginal childbirth.  This instrument is for external use only.

©2011 Plexus Biomedical, Inc. All rights reserved. Hem-Avert® is a registered trademark of Plexus Biomedical, Inc.


'/>"/>
SOURCE Plexus Biomedical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
2. BioMedical Enterprises, Inc. (BME) Introduces the HammerLock™ Shape Memory Device for Hammertoes.
3. Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS)
4. DSM Biomedical to be Key Contributor at the Surfaces in Biomaterials Foundations 2010 BioInterface Symposium and Workshop
5. DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials
6. ETC Biomedical Systems Offers New FDA Approved Hyperbaric Oxygen Therapy (HBOT) Medical Device
7. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
8. Crux Biomedical Named One of Top 50 Companies to Watch
9. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
10. Drexel Biomedical Researchers Develop Device to Predict Diabetic Wound Healing
11. West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Pa. , Dec. 5, 2016  Pennsylvania Physician ... Drug and Alcohol Programs Gary Tennis today ... drug, at Minnich,s Pharmacy in York ... order signed by Dr. Levine as a prescription to ... "It,s important to remember that any Pennsylvanian ...
(Date:12/5/2016)... India , December 5, 2016 According ... by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free ... published by MarketsandMarkets, the market is projected to reach USD 779.8 ... a CAGR of 13.5% during the forecast period of 2016 to ... ...
(Date:12/5/2016)... Sanovas, Inc., a life science asset holding company ... wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed Intubation ... http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed annually ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... The V Foundation for Cancer ... a Moment to Lose fundraising campaign. As the V Foundation’s boldest initiative to ... over cancer. The campaign aims to raise $200 million by 2020 and strategically ...
(Date:12/6/2016)... ... December 06, 2016 , ... Just in time for the holiday ... chocolate chip cookie recipe for Honeyville’s new Organic Quinoa Flour product for sale at ... in the near future. , “I think it’s wonderful that a growing number ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind ... design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... recount of a powerful woman's story of sacrifice and enlightenment. , ... published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... only authorized OSHA Training Institute Education Center headquartered in Northern California, has announced ... on providing occupational safety and health training to public sector employees. , “The ...
Breaking Medicine News(10 mins):